Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Acute Lymphoblastic Leukemia is a type of cancer which affects white blood cells. It is also called as Acute lymphocytic leukemia. IALL progresses rapidly without treatment. Acute lymphoblastic leukemia (ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. Symptoms of ALL includes fever, anemia, bleeding, blood clots, bone pain, rashes on skin, Palpable lymphadenopathy etc.

ALL is diagnosed by coagulation studies, blood tests, X-Ray, CT-Scan, ECG, MRI, bone marrow aspiration and biopsy etc. Treatment of ALL includes induction chemotherapy, consolidation chemotherapy, Stem cell transplantation and others.

 

Segmentation:

By Trial Phase, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Novartis
  • Pfizer
  • Ariad Pharmaceuticals
  • Juno Therapeutics
  • Janssen
  • Amgen
  • (Erytech Pharma
  • Bristol-Myers Squibb
  • Others

By Drugs, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Blinatumomab
  • Carfilzomib
  • calaspargasepegol
  • Dasatinib
  • Ibrutinib
  • Inotuzumabozogamicin
  • Ofatumumab
  • Ponatinib
  • Others

By Route of Administration, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Oral
  • Parenteral

 

Space Analysis:

  • In October 2015, Seattle Genetics, Inc.initiated randomized phase II clinical trial of denintuzumabmafodotin (SGN-CD19A) in combination with second-line salvage regimen of rituximab (Rituxan), ifosfamide, carboplatin and etoposide (RICE), for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
  • In September 2017, Kiadis pharma’s ATR101 was granted Regenerative Medicine Advanced Therapy (RMAT) designation by U.S.FDA and in April 2017, Kiadis pharma received regulatory approval from the national authority in Belgium to start pivotal Phase III trial with ATIR101™ and from the national authority in Germany to start the Phase I/II trial with ATIR201 for patients suffering from blood cancers

 

Report Description:

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Lymphoblastic Leukemia treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Lymphoblastic Leukemia disease pipeline drugs development. This report studies the dynamics of the Acute Lymphoblastic Leukemia Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Lymphoblastic Leukemia disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases
  • Novartis
  • Pfizer
  • Ariad Pharmaceuticals
  • Juno Therapeutics
  • Janssen
  • Amgen
  • (Erytech Pharma
  • Bristol-Myers Squibb

1. Executive Summary

 

2. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Introduction

 

2.1. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Taxonomy

2.2. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market –Definitions

2.2.1. Trial Phase

2.2.2. Drugs

2.2.3. Route of Administration

 

3. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics

 

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

 

3.4. Trends

 

3.5. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamic Factors – Impact Analysis

3.6. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Competition Landscape

3.7. Epidemiology

 

4. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024

 

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market opportunity analysis

 

5. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market, By Trail Phase, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1. Preclinical Trials

5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

 

5.2. Phase 1

5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

 

5.3. Phase 2

5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

 

5.4. Phase 3

5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

 

5.5. Phase 4

5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

 

6. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Forecast, By Drugs,2013 – 2017 and Forecast, 2017 – 2024

 

6.1. Blinatumomab

6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

 

6.2. Carfilzomib

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

 

6.3. Calaspargasepegol

6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

 

6.4. Dasatinib

6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

 

6.5. Ibrutinib

6.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.3. Market Opportunity Analysis

 

6.6. Inotuzumabozogamicin

6.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.6.3. Market Opportunity Analysis

 

6.7. Ofatumumab

6.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.7.3. Market Opportunity Analysis

 

6.8. Ponatinib

6.8.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.8.3. Market Opportunity Analysis

 

6.9. Others

6.9.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.9.3. Market Opportunity Analysis

 

7. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

7.1. Oral

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Parenteral

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

 

8. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1. North America

8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

 

8.2. Europe

8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

 

8.3. Asia-Pacific

8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

 

8.4. Latin America

8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

 

8.5. Middle East and Africa

8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

 

8.6. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

 

9. North America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.1. Trail Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

9.1.1. Preclinical Trials

9.1.2. Phase 1

9.1.3. Phase 2

9.1.4. Phase 3

9.1.5. Phase 4

 

9.2. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Blinatumomab

9.2.2. Carfilzomib

9.2.3. calaspargasepegol

9.2.4. Dasatinib

9.2.5. Ibrutinib

9.2.6. Inotuzumabozogamicin

9.2.7. Ofatumumab

9.2.8. Ponatinib

9.2.9. Others

 

9.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.3.1. Oral

9.3.2. Parenteral

 

9.4. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

 

9.5. North America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

9.6. North America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics – Trends

 

10. Europe Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

10.1. Trail Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Preclinical Trials

10.1.2. Phase 1

10.1.3. Phase 2

10.1.4. Phase 3

10.1.5. Phase 4

 

10.2. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Blinatumomab

10.2.2. Carfilzomib

10.2.3. calaspargasepegol

10.2.4. Dasatinib

10.2.5. Ibrutinib

10.2.6. Inotuzumabozogamicin

10.2.7. Ofatumumab

10.2.8. Ponatinib

10.2.9. Others

 

10.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Oral

10.3.2. Parenteral

 

10.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

 

10.5. Europe Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

10.6. Europe Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics – Trends

 

11. Asia-Pacific Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

11.1. Trail Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Preclinical Trials

11.1.2. Phase 1

11.1.3. Phase 2

11.1.4. Phase 3

11.1.5. Phase 4

 

11.2. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Blinatumomab

11.2.2. Carfilzomib

11.2.3. calaspargasepegol

11.2.4. Dasatinib

11.2.5. Ibrutinib

11.2.6. Inotuzumabozogamicin

11.2.7. Ofatumumab

11.2.8. Ponatinib

11.2.9. Others

 

11.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Oral

11.3.2. Parenteral

 

11.4. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       

 

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

 

11.5. Asia-Pacific Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

11.6. Asia-Pacific Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics – Trends

 

12. Latin America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

12.1. Trail Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Preclinical Trials

12.1.2. Phase 1

12.1.3. Phase 2

12.1.4. Phase 3

12.1.5. Phase 4

 

12.2. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Blinatumomab

12.2.2. Carfilzomib

12.2.3. calaspargasepegol

12.2.4. Dasatinib

12.2.5. Ibrutinib

12.2.6. Inotuzumabozogamicin

12.2.7. Ofatumumab

12.2.8. Ponatinib

12.2.9. Others

 

12.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Oral

12.3.2. Parenteral

 

12.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

 

12.5. Latin America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

12.6. Latin America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics – Trends

 

13. Middle East and Africa Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

13.1. Trail Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

13.1.1. Preclinical Trials

13.1.2. Phase 1

13.1.3. Phase 2

13.1.4. Phase 3

13.1.5. Phase 4

 

13.2. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Blinatumomab

13.2.2. Carfilzomib

13.2.3. calaspargasepegol

13.2.4. Dasatinib

13.2.5. Ibrutinib

13.2.6. Inotuzumabozogamicin

13.2.7. Ofatumumab

13.2.8. Ponatinib

13.2.9. Others

 

13.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Oral

13.3.2. Parenteral

 

13.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. Gulf Cooperation Council (GCC) Countries

13.4.2. Israel

13.4.3. South Africa

13.4.4. Rest of MEA

 

13.5. MEA Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

13.6. MEA Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics – Trends

 

14. Competition Landscape

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Novartis

14.2.2. Pfizer

14.2.3. Ariad Pharmaceuticals

14.2.4. Juno Therapeutics

14.2.5. Janssen

14.2.6. Amgen

14.2.7. (Erytech Pharma

14.2.8. Bristol-Myers Squibb

14.2.9. Others

 

15. Research Methodology

16. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553